Muriel D. David

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.

Journal: Oncoimmunology

Published: December 22, 2022

Serial transplantation unmasks galectin-9 contribution to tumor immune escape in the MB49 murine model.

Serial transplantation unmasks galectin-9 contribution to tumor immune escape in the MB49 murine model.

Journal: Scientific reports

Published: September 24, 2020

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Journal: Nature medicine

Published: November 05, 2017

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

Journal: ACS medicinal chemistry letters

Published: October 13, 2017

Phosphorylation of ARHGAP19 by CDK1 and ROCK regulates its subcellular localization and function during mitosis.

Phosphorylation of ARHGAP19 by CDK1 and ROCK regulates its subcellular localization and function during mitosis.

Journal: Journal of cell science

Published: July 12, 2017

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Journal: Blood

Published: April 13, 2017

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Journal: Cancer discovery

Published: September 15, 2016

Familial hematological malignancies: new IDH2 mutation.

Familial hematological malignancies: new IDH2 mutation.

Journal: Annals of hematology

Published: August 21, 2016

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.

Journal: Journal of inherited metabolic disease

Published: March 10, 2016

Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.

Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: November 04, 2015

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.

Journal: Blood cancer journal

Published: January 19, 2015

The RhoGAP ARHGAP19 controls cytokinesis and chromosome segregation in T lymphocytes.

The RhoGAP ARHGAP19 controls cytokinesis and chromosome segregation in T lymphocytes.

Journal: Journal of cell science

Published: November 22, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026